In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters

International Journal of Cancer

Volumn 135, Issue 7, 2014, Pages 1700-1710

  Durmus, Selvi ^a   Naik, Jyoti ^a,b   Buil, Levi ^a   Wagenaar, Els ^a   Van Tellingen, Olaf ^a   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

doxorubicin; hepatic uptake; OATP; pharmacokinetics

Indexed keywords

DOXORUBICIN; ORGANIC ANION TRANSPORTER; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1A2; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TISSUE LEVEL; DRUG TRANSPORT; FEMALE; HEK293 CELL LINE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMALL INTESTINE; TRANSGENIC MOUSE; WILD TYPE;

DOXORUBICIN; HEPATIC UPTAKE; OATP; PHARMACOKINETICS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; FEMALE; HEK293 CELLS; HUMANS; LIVER; MICE; MICE, TRANSGENIC; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; TISSUE DISTRIBUTION;

EID: 84904462921     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28797     Document Type: Article

References (42)

1. Hagenbuch B, Meier PJ,. Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch 2004; 447: 653-65.
2. Obaidat A, Roth M, Hagenbuch B,. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 2012; 52: 135-51.
3. Cheng X, Klaassen CD,. Tissue distribution, ontogeny, and hormonal regulation of xenobiotic transporters in mouse kidneys. Drug Metab Dispos 2009; 37: 2178-85.
4. Cheng X, Maher J, Chen C, et al. Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps). Drug Metab Dispos 2005; 33: 1062-73.
5. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007; 81: 362-70.
6. Lee W, Glaeser H, Smith LH, et al. Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005; 280: 9610-17.
7. Gao B, Hagenbuch B, Kullak-Ublick GA, et al. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol Exp Ther 2000; 294: 73-9.
8. Abe T, Unno M, Onogawa T, et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 2001; 120: 1689-99.
9. Konig J, Cui Y, Nies AT, et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156-G164.
10. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273: 251-60.
11. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, et al. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 2008; 68: 9338-47.
12. Liedauer R, Svoboda M, Wlcek K, et al. Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol Rep 2009; 22: 1485-92.
13. Arakawa H, Nakanishi T, Yanagihara C, et al. Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochem Pharmacol 2012; 84: 1070-7.
14. Svoboda M, Wlcek K, Taferner B, et al. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother 2011; 65: 417-26.
15. Ballestero MR, Monte MJ, Briz O, et al. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol 2006; 72: 729-38.
16. Konig J, Seithel A, Gradhand U, et al. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-43.
17. Maeda K, Sugiyama Y,. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 2008; 23: 223-35.
18. Pasanen MK, Neuvonen PJ, Niemi M,. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008; 9: 19-33.
19. Laitinen A, Niemi M,. Frequencies of single-nucleotide polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 genes in a Finnish population. Basic Clin Pharmacol Toxicol 2011; 108: 9-13.
20. Yamakawa Y, Hamada A, Shuto T, et al. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin Pharmacol Ther 2011; 90: 157-63.
21. Kalliokoski A, Niemi M,. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705.
22. Takane H, Kawamoto K, Sasaki T, et al. Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 2009; 63: 1165-9.
23. Trevino LR, Shimasaki N, Yang W, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol 2009; 27: 5972-8.
24. van de Steeg E, Stranecky V, Hartmannova H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122: 519-28.
25. Weiss RB, Sarosy G, Clagett-Carr K, et al. Anthracycline analogs: the past, present, and future. Cancer Chemother Pharmacol 1986; 18: 185-97.
26. Gewirtz DA,. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999; 57: 727-41.
27. Vlaming ML, Mohrmann K, Wagenaar E, et al. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 2006; 318: 319-27.
28. van Asperen J, van Tellingen O, Beijnen JH,. The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice. Drug Metab Dispos 2000; 28: 264-7.
29. van Asperen J, van Tellingen O, Tijssen F, et al. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br J Cancer 1999; 79: 108-13.
30. Allen JD, Brinkhuis RF, Wijnholds J, et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 1999; 59: 4237-41.
31. Okabe M, Unno M, Harigae H, et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 2005; 333: 754-62.
32. van de Steeg E, Wagenaar E, van der Kruijssen CM, et al. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010; 120: 2942-52.
33. van de Steeg E, van EA, Wagenaar, E, et al. High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin Cancer Res 2011; 17: 294-301.
34. Peters J, Eggers K, Oswald S, et al. Clarithromycin is absorbed by an intestinal uptake mechanism that is sensitive to major inhibition by rifampicin: results of a short-term drug interaction study in foals. Drug Metab Dispos 2012; 40: 522-8.
35. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004; 311: 139-46.
36. van de Steeg E, van der Kruijssen CM, Wagenaar E, et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 2009; 37: 277-81.
37. van Asperen J, van Tellingen O, Beijnen JH,. Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 712: 129-43.
38. de Graan AJ, Lancaster CS, Obaidat A, et al. Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel. Clin Cancer Res 2012; 18: 4433-40.
39. Gong S, Lu X, Xu Y, et al. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 2002; 30: 1162-9.
40. Iusuf D, van EA, Hobbs, M, et al. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure. Mol Pharmacol 2013; 83: 919-29.
41. Watanabe T, Kusuhara H, Maeda K, et al. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 2009; 328: 652-62.
42. Hagenbuch B, Gui C,. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008; 38: 778-801.